Nureca Limited has secured board approval for a share buyback worth up to ₹191.4 million, following SEBI's exemption amid a pending merger. The move, decided on November 28, 2025, targets public shareholders exclusively and signals confidence in the home healthcare leader's growth trajectory.
Buyback Approval Details
Nureca Limited , known for brands like Dr Trust and Dr Physio in home healthcare and wellness, approved the buyback proposal at its board meeting on November 28, 2025. This follows SEBI's nod for an exemption from buyback regulations during its internal merger with Nureca Technologies Private Limited, ensuring no change in shareholding. Promoters opted out, reserving the opportunity for public investors to tender shares.
Strategic Context
The buyback aims to optimize capital structure, enhance earnings per share, and return value amid steady sector demand. Shares hit a 5% upper circuit at ₹267.5 post-announcement buzz, reflecting market optimism despite past sales challenges. Trading window closed from November 26 to December 2 for compliance.
Key Highlights
Buyback Size: Up to ₹191.4 million (₹19.14 crore) via open market or tender process.
Eligibility: Exclusive to public shareholders; promoters abstain.
Regulatory Nod: SEBI exemption granted October 2025 for merger overlap.
Share Impact: Pre-buyback pattern detailed; potential EPS uplift.
Next Steps: Shareholder approval, record date, and execution timeline to follow.
Sources: NSE India filings, Business Standard, SEBI order.